Literature DB >> 7687088

A study of the interrelationship between circulating IgG subclass anti-IgE autoantibodies, IgE and soluble CD23 in asthma.

F Shakib1, L Boulstridge, S J Smith.   

Abstract

In this paper we hypothesise that circulating autoanti-IgE antibodies, which are found in allergic asthma patients, could potentially enhance IgE synthesis by blocking its binding to CD23 on B lymphocytes, thereby potentiating the release of soluble fragments of CD23 which have B cell growth-promoting activity. We have investigated this possibility indirectly by measuring soluble (s) CD23 and IgG subclass anti-IgE antibody levels in asthmatic patients' sera, to find out if the two parameters are related. However, we were unable to show any significant correlations between serum IgG subclass anti-IgE activities and sCD23 levels. This may have been due, at least in part, to the heterogeneous epitope specificity of the autoanti-IgE being detected. Interestingly, there was a significant inverse correlation (p = 0.0178) between serum IgE and sCD23 levels in asthma; an observation which underlines the notion that binding of IgE to membrane CD23 abrogates the release of sCD23. The present study confirms and extends previous reports of significantly raised circulating levels of IgG anti-IgE in asthma patients (p = 0.0004), by further demonstrating that IgG anti-IgE is mostly restricted to IgG1. Given that IgG1 binds very efficiently to C1q and Fc gamma Rs, our observation lends further support to the notion that IgG anti-IgE may facilitate the removal of IgE-allergen complexes by triggering IgG effector function pathways.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687088

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  1 in total

1.  Circulating human IgG autoanti-IgE antibodies in asthma patients block the binding of IgE to its high affinity receptor.

Authors:  S J Smith; A Galvin; I Hall; F Shakib
Journal:  Clin Mol Pathol       Date:  1995-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.